Chiral Naphthyl-C2-Indole as Scaffold for Phosphine Organocatalysis: Application in Asymmetric Formal [4 + 2] Cycloaddition Reactions
作者:Tingting He、Lei Peng、Shan Li、Fangli Hu、Chuandong Xie、Shengli Huang、Shiqi Jia、Wenling Qin、Hailong Yan
DOI:10.1021/acs.orglett.0c02519
日期:2020.9.4
naphthyl-C2-indole bifunctional phosphine organocatalyst in stereoselective formal [4 + 2] cycloadditionreactions were reported. The chiral naphthyl-C2-indole skeleton was introduced to bifunctional phosphine organocatalysis for the first time, and excellent stereocontrol was achieved in two types of formal [4 + 2] cycloadditionreactions. With the optimal catalyst, a series of chiral spirooxindole and hydrodibenzofuran
Tertiary Amine-Catalyzed Difluoromethylthiolation of Morita-Baylis-Hillman Carbonates of Isatins with Zard's Trifluoromethylthiolation Reagent
作者:Xing Fan、Haibin Yang、Min Shi
DOI:10.1002/adsc.201600954
日期:2017.1.4
tertiary amine‐catalyzed [3+2] annulation between Morita–Baylis–Hillman (MBH) carbonates derived from isatins with thiocarbonyl fluoride (F2C=S) in situ generated from Zard's reagent proceeds smoothly under mild conditions, affording difluoromethylthiolated spirocyclic oxindoles in good to excellent yields. Moreover, the asymmetric variant could be realized with a modified Cinchonaalkaloid, giving the
在本文中,我们报道了一种新的叔胺催化的[3 + 2]环化反应,该反应是由Isards衍生的Morita–Baylis–Hillman(MBH)碳酸酯与异硫氰酸羰基氟化物(F 2 C = S)从Zard试剂原位生成的在温和的条件下,以良好或优异的收率得到二氟甲基硫醇化的螺环羟吲哚。此外,可以用修饰的金鸡纳生物碱实现不对称变体,从而以良好的对映体选择性以及良好的产率获得所需的环状加合物。
[EN] N-[(AMINOSULFONYL)PHENYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-HYDRAZINECARBOTHIOAMIDE DERIVATIVES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS<br/>[FR] DÉRIVÉS DE N-[(AMINOSULFONYL)PHÉNYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDÈNE)-HYDRAZINECARBOTHIOAMIDE POUR LE TRAITEMENT DU CANCER ET DE TROUBLES IMMUNOLOGIQUES
申请人:ISTANBUL UNIV REKTORLUGU
公开号:WO2017099695A1
公开(公告)日:2017-06-15
N-[(aminosulfonyl)phenyl]-2-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-hydrazinecarbothioamide derivatives of the following formula (III) for treating cancer and immunological disorders. R5, R6 and R7 are each independently selected from hydrogen and a sulfonamide group, provided that at least one of R5, R6 or R7 is a sulfonamide group. The substituents R1 to R4 are each independently either hydrogen or one of the substituents defined in the claims.